Novo Nordisk A/S $NVO Stock Holdings Reduced by Migdal Insurance & Financial Holdings Ltd.

Migdal Insurance & Financial Holdings Ltd. reduced its position in Novo Nordisk A/S (NYSE:NVO) by 99.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,780 shares of the company’s stock after selling 340,609 shares during the period. Migdal Insurance & Financial Holdings Ltd.’s holdings in Novo Nordisk A/S were worth $192,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. NewSquare Capital LLC raised its position in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares in the last quarter. Disciplina Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 297 shares during the last quarter. Mid American Wealth Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter worth $37,000. State of Wyoming bought a new position in shares of Novo Nordisk A/S during the 1st quarter valued at $38,000. Finally, Maseco LLP acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at $39,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $50.12 on Monday. The company’s fifty day moving average is $50.86 and its two-hundred day moving average is $58.29. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $109.88. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The firm has a market capitalization of $223.79 billion, a price-to-earnings ratio of 14.57 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The business had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analysts Set New Price Targets

NVO has been the topic of several recent research reports. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating for the company in a research report on Tuesday, November 25th. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, Jefferies Financial Group started coverage on shares of Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $53.33.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.